CLAIMS

1. Use of a rAAV particle in the manufacture of a medicament for the treatment of an ocular disorder, wherein the rAAV particles comprises:

a) a rAAV capsid comprising an AAV2 capsid protein comprising one or more amino acid substitutions at one or more positions R484, R487, K527, K532, and/or R588, numbering based on VP1 numbering of AAV2,

wherein the one or more amino acid substitutions is with a hydrophobic amino acid residue,

wherein the one or more amino acid substitutions reduces binding of the rAAV particle to a heparin sulfate proteoglycan, and

b) a rAAV vector comprising a heterologous nucleic acid and at least one AAV terminal repeat.

2. The use of claim 1, wherein the one or more amino acid substitutions reduces binding of the rAAV particle to the heparan sulfate proteoglycan by about at least 10%, about at least 25%, about at least 50%, about at least 75%, or about at least 100%.

3. The use of any one of claims 1-2, wherein the one or more amino acid substitutions comprises substitution of an arginine or lysine residue.

4. The use of any one of claims 1-3, wherein the one or more amino acid substitutions comprises substitution of an arginine or lysine residue with an alanine residue.

5. The use of any one of claims 1-4, wherein the one or more amino acid substitutions is at position R484, R487, or K532, numbering based on VP1 numbering of AAV2.

6. The use of any one of claims 1-5, wherein the rAAV particle comprises one or more AAV2 capsid proteins having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NOs:2, 4 and/or 6.

7. The use of any one of claims 1-5, wherein the one or more amino acid substitutions comprises substitutions at positions R484 and R487 or at positions R585 and R588, numbering based on VP1 of AAV2.

8. The use of any one of claims 1-5, wherein the one or more amino acid substitutions comprises R484A and R487A substitutions or R585A and R588A substitutions, numbering based on VP1 of AAV2.

9. The use of any one of claims 1-5, wherein the AAV2 capsid protein comprises amino acid substitutions R585A and R588A, numbering based on VP1 of AAV2.

10. The use of any one of claims 1-5, wherein the AAV2 capsid protein comprises amino acid substitution K532A, numbering based on VP1 of AAV2.